The Tough Tech problem we are solving
Precision medicine is revolutionizing oncology, with targeted therapies that improve and extend cancer patients’ lives. But precision diagnostics have fallen behind. In their clinical practices at the Dana-Farber Cancer Institute, physician-scientists Dr. Irene Ghobrial and Dr. Kenneth Anderson saw firsthand this gap between the state-of-the-art immunotherapies increasingly at their disposal, and the archaic diagnostic processes available to help them in their treatment decisions. “Most of the drugs we use are targeted therapies,” says Dr. Ghobrial, “but we often don’t know which patients will or will not respond.” And for blood cancers, like multiple myeloma, even those limited tests require a bone marrow biopsy—a painful surgical procedure, which often yields limited clinical value.
About our solution
Predicta Biosciences, a precision oncology startup, has developed an innovative diagnostics platform that uses multiomic data to enable diagnosis, guide precision treatment, and unlock novel therapies. Its proprietary laboratory workflow is highly efficient at isolating circulating tumor cells from blood samples alone, while still allowing for whole-genome DNA and single-cell RNA sequencing of even early stage cancers. For patients, that means a blood draw rather than a painful bone marrow biopsy. For clinicians, Predicta offers unique access to an unprecedented level of data that can guide treatment.